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Key messages
What is already known about this subject?
 ► Patients with psoriasis have a period of non-specific 
joint symptoms (ie, arthralgia) before psoriatic ar-
thritis (Psa) development, but the anatomical basis 
for such arthralgia remains to be defined.
What does this study add?
 ► tenosynovitis could be an important contributor to 
non-specific musculoskeletal symptoms in psoriatic 
patients with arthralgia (PsOar).
 ► clinically, PsOar patients were more prone to devel-
op Psa with longitudinal evaluation and the baseline 
sonographic detection of enthesitis was associated 
with clinical Psa development.
How might this impact on clinical practice?
 ► PsOar patients could be a subgroup of psoriatic pa-
tients in which a strict rheumatological monitoring or 
disease interception with psoriasis directed therapy 
could be envisaged.
AbstrAct
Objective non-specific musculoskeletal pain is common 
in subjects destined to develop psoriatic arthritis (Psa). 
We evaluated psoriatic patients with arthralgia (PsOar) 
compared with psoriasis alone (PsO) and healthy controls 
(Hcs) using ultrasonography (US) to investigate the 
anatomical basis for joint symptoms in PsOar and the 
link between these imaging findings and subsequent Psa 
transition.
Methods a cross-sectional prevalence analysis of 
clinical and US abnormalities (including inflammatory 
and structural lesions) in PsOar (n=61), PsO (n=57) and 
Hcs (n=57) was performed, with subsequent prospective 
follow-up for Psa development.
Results tenosynovitis was the only significant 
sonographic feature that differed between PsOar and 
PsO (29.5% vs 5.3%, p<0.001), although synovitis and 
enthesitis were numerically more frequent in PsOar. Five 
patients in PsOar and one in PsO group developed Psa, 
with an incidence rate of 109.2/1000 person-years in 
PsOar vs 13.4/1000 person-years in PsO (p=0.03). Visual 
analogue Scale pain, Health assessment Questionnaire, 
joint tenderness and US active enthesitis were baseline 
variables associated with Psa development.
Conclusion tenosynovitis was associated with arthralgia 
in subjects with psoriasis. Baseline US evidence of 
enthesitis was associated with clinical Psa development 
in the longitudinal analysis. these findings are relevant 
for enriching for subjects at risk of imminent Psa 
development.
InTROduCTIOn
Psoriatic arthritis (PsA) is a common and 
potentially debilitating arthropathy that can 
occur in up to a third of patients with psori-
asis.1 It is well established that joint damage 
can occur early in the course of PsA, so early 
disease recognition is imperative. Given that 
psoriasis predates PsA by a decade or more, 
then skin involvement offers the opportunity 
to investigate risk factors and predictors of 
PsA development.2 The incidence of PsA in 
different psoriasis cohorts is between 0.3% 
and 3.5% per annum.2 3 In rheumatoid 
arthritis, anti citrullinated protein antibodies 
(ACPA)+ cases have a preclinical phase of 
disease characterised by clinically suspected 
arthralgia4 and imaging studies have shown 
that this phase of disease is associated with 
synovitis and tenosynovitis.5 6
In PsA, it was clinically recognised that 
the complex of symptoms, experienced 
by patients in their preclinical phases of 
disease, is heterogeneous, from fatigue and 
depressive symptoms to arthralgia. However, 
prospective studies focussing on symptoms 
suspicious for PsA development are still 
lacking. Recently, Eder et al showed in a 
longitudinal cohort of psoriasis that cases 
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box 1 Inclusion and exclusion criteria
Inclusion criteria
1. age ≥18 years
2. current cutaneous psoriasis and/or nail psoriasis diagnosed by a 
dermatologist
3. negative history of arthritis, dactylitis, enthesitis or inflammatory 
back pain
4. absence of clinical signs of osteoarthritis* and/or fibromyalgia†
5. absence of signs of active arthritis, dactylitis, enthesitis or inflam-
matory back pain atenrolment, evaluated by rheumatologist
Exclusion criteria
1. Satisfaction of caSPar criteria
2. Use of conventional synthetic DMarDs, steroid therapy (oral and 
intra-articular), retinoids, non-steroidal anti-inflammatory drugs 
(chronically)within 3 months from enrolement
3. Previous or actual use of bDMarDs or small molecules (eg, 
Phosphodiesterase-4 inhibitor [PDe4i])
*the clinical diagnosis of osteoarthritis was ruled out by a rheumatologist. 
†Fibromyalgia was tested by acr criteria (Wolfe et al. arthritis care res 
(Hoboken). 2010 May;62(5):600–10)
destined to developed PsA had antedating non-spe-
cific musculoskeletal symptoms, without distinct find-
ings suggestive for PsA on physical examination.7 The 
anatomical basis for joint pain in the preclinical phase 
of PsA is not yet understood, and musculoskeletal 
ultrasonography (US) could be a reliable modality to 
detect musculoskeletal inflammatory lesions in these 
patients with psoriasis.8–11 Moreover, this sonograph-
ic-determined inflammation appears to regress under 
systemic therapy for skin disease raising the possibility 
that skin-directed therapy may prevent arthritis devel-
opment.12 However, the current inability to accurately 
enrich for imminent PsA means that the question of 
PsA prevention strategies remains in its infancy.13
In this study we explored, by means of US, the anatom-
ical basis for arthralgia in subjects with psoriasis. We 
followed up this patient group looking at the rate of PsA 
development in patients with psoriasis with and without 
arthralgia and linked this to baseline imaging findings. 
Our findings confirmed that arthralgia in subjects with 
psoriasis is associated with PsA development with our 
imaging data showing important roles for baseline imag-
ing-determined tenosynovitis or enthesitis on both symp-
toms and disease evolution.
METHOds
study population
Patients with psoriasis and age-matched randomly 
selected healthy controls (HCs) were recruited from 
rheumatology and dermatology clinics from seven 
centres in Italy. The HCs were non-blood relatives of 
enrolled patients or dermatological patients with other 
skin disease. Before enrolment all subjects were eval-
uated by rheumatologists in order to exclude inflam-
matory arthritis and/or spondylitis, either current 
or in the past (ie, current or negative history of 
arthritis, dactylitis, enthesitis or inflammatory back 
pain) (box 1). Patients with psoriasis were divided in 
psoriasis cases with arthralgia (PsOAr) and without 
arthralgia (PsO). The PsOAr was defined as recent 
onset (≤12 months) of non-inflammatory joint and/or 
entheseal pain, without current or past inflammatory 
signs/symptoms, and with Classification Criteria for 
Psoriatic Arthritis (CASPAR) criteria for a diagnosis of 
PsA not being fulfilled (box 1).14 Concomitant osteo-
arthritis and fibromyalgia were also excluded. Previous 
or current use of biological disease-modifying antirheu-
matic drugs (DMARDs) or small molecules, and the 
use, within 3 months from enrolment, of conventional 
synthetic DMARDs, steroid therapy (oral and intra-ar-
ticular), retinoids, non-steroidal anti-inflammatory 
drugs (chronically) were stated as exclusion criteria. 
Inclusion and exclusion criteria are detailed in box 1. 
All patients gave oral and written informed consent for 
all procedures, which were carried out in accordance 
with the Declaration of Helsinki and with the guide-
lines for Good Clinical Practice.
study design
The study consisted of two phases: (a) cross-sectional 
prevalence analysis of clinical and US abnormalities in 
PsOAr compared with PsO and HCs; (b) prospective 
analysis looking for the development of PsA. The diag-
nosis of PsA was clinical and made by rheumatologists, 
blinded to previous US results, if CASPAR criteria were 
fulfilled. In the prospective follow-up, all psoriasis partic-
ipants were reassessed every 6 months or according to 
clinical practice. Patients were instructed to contact the 
rheumatologist prior to their scheduled assessment if 
they developed inflammatory symptoms (eg, worsening 
of joint pain, morning stiffness). In the prospective 
phase, only patients with psoriasis with a follow-up of at 
least 3 months were included for final analysis. In order 
to increase the validity and reliability of the results, the 
participants satisfied prerequisites: (1) expertise in early 
PsA and in combined dermatological-rheumatological 
assessment; (2) availability of a high-level US machine 
including high-level US probes (>14 MHz); (3) reliability 
exercise on US static images with a kappa statistics value 
>0.7 compared with ‘gold-standard’ scorers (AZ, AI) 
(table 1).
Clinical assessment
For each patient, we recorded demographic data, 
including age, sex, body mass index (BMI), smoking 
history, alcohol intake and comorbidities (obesity, 
diabetes, hypertension, metabolic syndrome, fatty liver 
disease, inflammatory bowel disease, uveitis, depression, 
neoplastic disease, cardiovascular disease). Articular and 
entheseal examination, including tender joints count 
(68 joints) and tender entheses count at six entheses, 
as defined by Leeds Enthesitis Index, plus quadriceps 
patellar insertion, proximal and distal patellar insertion 
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Table 1 Ultrasonographic definitions of inflammatory and damage lesions and agreement between sonographers expressed 
by Kappa value
Ultrasonographic 
lesion Definition
Grey scale (GS) 
synovitis
GS synovitis was evaluated by including its two components (ie, joint effusion and synovial 
membrane hypertrophy), which was assessed according to the OMERACT definitions.26 In GS, 
the two components of synovitis (ie, joint effusion and synovial hypertrophy) was scored together 
according to a 4-point semi-quantitative assessment as follows: synovitis: grade 0=no synovitis; 
grade 1=minimal synovitis (below or at the level of bony joint line); grade 2=moderate synovitis 
(above level of bony joint line but without full distension of joint capsule); grade 3=severe synovitis 
(above level of bony joint line with distension of joint capsule which will appear convex).27 28
Power Doppler (PD) 
synovitis
PD synovitis was scored by using a semi-quantitative 4-point scale, as follows: grade 0=no flow 
within the synovium; grade 1=up to three single spots signals or up to two confluent spots signals or 
one confluent spot+up to two single spots signals; grade 2=PD signals covering <50% of the area of 
the synovium; grade 3=PD signals in >50% of the area of the synovium.29
Joint erosion Erosions were defined as intra-articular discontinuity of the bone surface that is visible in two 
perpendicular planes.26
Joint osteoproliferation The OMERACT definition of osteophyte (osteoproliferation at the joint margins) was used.30
GS tenosynovitis GS tenosynovitis was defined on GS as abnormal anechoic and/or hypoechoic (relative to tendon 
fibres) tendon sheath widening, which can be related to both the presence of tenosynovial abnormal 
fluid and/or hypertrophy. On GS, tenosynovitis was graded according to a 4-point semi-quantitative 
scoring system as follows: grade 0=normal; grade 1=minimal; grade 2=moderate; grade 3=severe. 
Both longitudinal and transverse planes were performed in order to confirm the findings.31
PD tenosynovitis PD tenosynovitis was defined as the presence of peritendinous Doppler signal within the synovial 
sheath, seen in two perpendicular planes, excluding normal feeding vessels (ie, vessels at the 
mesotenon or vinculae or vessels entering the synovial sheath from surrounding tissues) only if 
the tendon shows peritendinous synovial sheath widening on B-mode. A 4-point semi-quantitative 
scoring system (ie, grade 0=no Doppler signal; grade 1=minimal; grade 2=moderate; grade 
3=severe) can be used to score pathological peritendinous Doppler signal within the synovial 
sheath.31
Enthesitis Enthesitis was defined in accordance with the recently published OMERACT definitions and the 
registered elementary lesions will be: hypoechogenicity of the enthesis (hypoechoic tendon with 
loss of the normal fibrillar pattern); increased thickness of tendon at its insertion*; enthesophyte (a 
step up bony prominence at the end of the normal bone contour); calcifications; bone erosion at the 
enthesis; PD activity at enthesis <2 mm from the bone insertion.17
Bursitis Bursitis will be defined as an abnormal distension of the bursal wall, due to local effusion and/or 
synovial proliferation. PD signal was evaluated as present/absent.32
Peritendinits of the 
extensor tendon on 
metacarpophalangeal 
joint
The presence of peritenon extensor tendon inflammation was investigated by dorsal scans at the 
level of all fingers of both hands. This abnormality was defined as a hypoechoic swelling of the soft 
tissues surrounding the extensor digitorum tendons, with or without peritendinous PD signal.33 34
OMERACT, Outcome Measures in Rheumatology.
Sonographer Observed agreement Expected change agreement Kappa value
1 0.88 0.36 0.82
2 0.90 0.37 0.85
3 0.97 0.37 0.95
4 0.83 0.39 0.72
5 0.93 0.37 0.92
Kappa value=(observed agreement–expected change agreement)/(1–expected change agreement).
*Entheseal thickening measured at 2 mm proximal to the bony contour (abnormality definitions: quadriceps tendon >6.1 mm, proximal and 
distal patellar ligament >4 mm, Achilles tendon >5.29 mm, plantar aponeurosis >4.4 mm).32
and plantar fascia was performed by a rheumatologist. 
Articular regions that had suffered from prior bone 
fractures or had undergone surgical procedures were 
excluded from the clinical examination. Each patient 
completed a Visual Analogue Scale (VAS) for muscu-
loskeletal pain and a Health Assessment Question-
naire (HAQ) to document physical function. Psoriasis 
subtype, nail involvement, age at disease onset and 
M
edical Library. Protected by copyright.
 o
n
 January 7, 2020 at Assistant Librarian St Jam
es`s Hospital
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2019-001067 on 23 O
ctober 2019. Downloaded from
 
4 Zabotti a, et al. RMD Open 2019;5:e001067. doi:10.1136/rmdopen-2019-001067
RMD Open
Table 2 Baseline features of the study cohorts
HCs (n=57) PsO (n=57) PsOAr (n=61)
P value
PsOAr vs 
PsO vs 
HCs
P value
PsO vs 
HCs
P value
PsOAr vs 
HCs
P value
PsOAr vs 
PsO
Baseline data
  Age, mean (±SD) 47.91 (±13.03) 50.65 (±16.62) 50.49 (±12.27) 0.44 n.a. n.a. n.a.
  Female, n (%) 39 (69.64%) 28 (49.12%) 34 (55.74%) 0.08 n.a. n.a. n.a.
  Smoking, n (%) 8 (14.55%) 17 (29.82%) 5 (8.2%) 0.02 0.14 0.15 0.008
  BMI, mean (±SD) 23 (±3.67) 25 (±3.95) 26 (±4.8) <0.001 0.002 0.001 0.96
  Family history of 
PsA, n (%)
1 (1.75%) 9 (16.07%) 7 (11.48%) 0.02 0.008 0.062 0.59
  Diabetes mellitus, 
n (%)
2 (3.51%) 3 (5.26%) 5 (8.2%) 0.61 n.a. n.a. n.a.
  Hypertension, n 
(%)
6 (10.53%) 11 (19.3%) 19 (31.15%) 0.03 0.29 0.007 0.20
  Metabolic 
syndrome, n (%)
4 (7.02%) 4 (7.02%) 11 (18.03%) 0.10 n.a. n.a. n.a.
  Depression, n (%) 1 (1.75%) 3 (5.26%) 9 (14.75%) 0.03 0.62 0.017 0.13
Patient-reported symptoms and baseline clinical examination
  VAS pain (0–10), 
mean (±SD)
2 (±2) 2 (±2.39) 4 (±2.35) <0.001 0.97 <0.001 <0.001
  HAQ, mean (±SD) 0 (±0.21) 0 (±0.48) 0 (±0.39) <0.001 0.05 <0.001 <0.001
  Tender joints 
count, mean (±SD)
0.37 (±1.1) 0.49 (±0.98) 2.98 (±4.7) <0.001 0.14 <0.001 <0.001
  Tender enthesis 
count, mean (±SD)
0.02 (±0.13) 0.09 (±0.34) 0.64 (±1.14) <0.001 0.17 <0.001 <0.001
  PASI, mean (±SD) n.a. 3.79 (±3.29) 4.34 (±5.65) n.a. n.a. n.a. 0.92
  NAPSI, mean 
(±SD)
n.a. 9.07 (±8.50) 8.48 (±7.95) n.a. n.a. n.a. 0.76
Joints tenderness was evaluated in 68 joints. Tender entheses count was evaluated in six sites of LEI plus bilateral quadriceps patellar 
insertion, proximal and distal patellar insertion and plantar fascia.
Values in bold signifies p value ≤0.05.
BMI, body mass index; HAQ, Health Assessment Questionnaire; HC, healthy control; LEI, Leeds enthesitis index; n.a., not applicable; NAPSI, 
Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis alone; PsOAr, psoriatic patients 
with arthralgia; VAS, Visual Analogue Scale.
previous medications for cutaneous or nail psoriasis were 
recorded. Severity of psoriasis and nail involvement were 
scored according to the Psoriasis Area and Severity Index 
(PASI) and Nail Psoriasis Severity Index (NAPSI), respec-
tively.
ultrasonographic assessment
All sonographers were rheumatologists with experi-
ence (≥5 years) in US examinations of PsA and blinded 
to diagnosis and clinical findings. To standardise and 
reach an agreement on the US definitions a meeting 
was organised before the starting of the study. In addi-
tion, all sonographers had a booklet with standard US 
imaging instructions. Reliability exercise on static images 
was performed before the start of the study (table 1). 
US analysis was performed in the same day of clinical 
examination and focused in a longitudinal and trans-
verse scan of 42 regions encompassing the following: 
metacarpophalangeal, proximal and distal interphalan-
geal joints of the hands, wrists, knees, metatarsophalan-
geal joints, 12 entheses (Achilles, quadriceps, proximal 
and distal patellar, plantar aponeurosis and common 
extensor tendon entheses), the 2 retro-calcaneal bursae 
and 32 tendons (extensor digitorum tendons of the 
hands, flexor digitorum tendons of the hands and 
extensor tendon compartments of the wrist). As for clin-
ical examination, articular regions that had suffered from 
prior bone fractures or had undergone surgical proce-
dures were excluded from the US examination. The sites 
to be scanned and US definitions of inflammatory lesions 
(ie, synovitis, tenosynovitis, enthesitis, peritenon extensor 
tendon inflammation and bursitis) and damage lesions 
(ie, joint erosions, entheseal erosions, enthesophytes and 
articular osteoproliferation) were defined according to 
a previous protocol9 15 16 and are presented in table 1. 
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Figure 1 Prevalence of ultrasonographic lesion in HCs, PsO and PsOAr expressed as percentage of patients with at least 
one feature and as the mean number (*) of US lesion per patient. HC, healthy control; PsO, psoriasis alone; PsOAr, psoriatic 
patients with arthralgia; US, ultrasonography.
Active synovitis was defined if both articular grey scale 
(GS) synovitis (GS ≥2) and intra-articular power Doppler 
(PD) signal (PD ≥1) were detected. Active enthesitis was 
defined by the lack of the homogeneous fibrillar pattern 
in the enthesis (<2 mm from the cortical bone) with loss 
of the tightly packed echogenic lines after correcting for 
anisotropy with concomitant PD signal at bone insertion 
(<2 mm from the cortical bone).9 17
statistical analysis
Quantitative variables were presented as the mean 
and SD, median and IQR. Categorical variables were 
presented as absolute frequencies and percentages. 
Comparisons between independent means were analysed 
using Wilcoxon Mann-Whitney U test while, to test the 
difference between groups, accurate Fisher’s exact test 
for categorical variables and Kruskal-Wallis for contin-
uous variables were used. In the longitudinal analysis, 
the incidence rates were compared by using Fisher’s 
exact test. This is the first study to assess the anatomic 
basis for arthralgia and their linkage with PsA develop-
ment in subjects with psoriasis by means of US. Consid-
ering the sample size, possible number of events and 
the wide range of clinical and US predictors this analysis 
was considered exploratory. A predictive model for PsA 
development was not feasible, therefore the association 
between groups based on the presence of event (ie, PsA 
development) was made. Data management and analysis 
were performed using REDCap and R software.
REsulTs
Cross-sectional study
Sixty-one PsOAr, 57 PsO and 57 HCs were included 
from 7 Italian centres for the cross-sectional analysis. 
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Table 3 Association between sonographic detected active synovitis and enthesitis with baseline clinical data
Event Nonevent P value Event Non-event P value
Active synovitis in PsO (n=57) Active synovitis in PsOAr (n=61)
Age, mean (±SD) 58.93 (±11.14) 47.69 (±17.35) 0.019 51.05 (±10.03) 50.2 (±13.41) 0.74
Female, n (%) 5 (33.33%) 23 (54.76%) 0.23 10 (47.62%) 24 (60%) 0.42
Smoking, n (%) 3 (20%) 14 (33.3%) 0.483 0 5 (12.5%) 0.18
BMI, mean (±SD) 26.52 (±3.32) 25.05 (±4.12) 0.195 26.73 (±4.5) 25.48 (±4.96) 0.23
Alcohol, n (%) (daily intake) 0 0 0.817 0 0 0.47
Diabetes mellitus, n (%) 1 (6.67%) 2 (4.76%) 1 2 (9.52%) 3 (7.5%) 1
Hypertension, n (%) 2 (13.33%) 9 (21.43%) 0.709 6 (28.57%) 13 (32.5%) 1
Metabolic syndrome, n (%) 0 (0%) 4 (9.52%) 0.564 4 (19.05%) 7 (17.5%) 1
HAQ, mean (±SD) 0.17 (±0.28) 0.21 (±0.53) 0.886 0.23 (±0.22) 0.43 (±0.45) 0.14
VAS, mean (±SD) 1.57 (±1.99) 1.96 (±2.53) 0.885 4.02 (±2.72) 3.65 (±2.15) 0.84
PASI, mean (±SD) 4.57 (±4.15) 3.53 (±2.94) 0.489 4.42 (±2.76) 4.30 (±6.80) 0.09
NAPSI, mean (±SD) 9.17 (±5.62) 9.03 (±9.43) 0.390 13.7 (±7.74) 5.07 (±6.18) 0.014
Values in bold signifies p value ≤0.05.
 Active enthesitis in PsO (n=57) Active enthesitis in PsOAr (n=61)
Age, mean (±SD) 57.2 (±11.78) 49.26 (±17.26) 0.2 54.18 (±6.93) 49.07 (±13.6) 0.16
Female, n (%) 2 (20%) 26 (55.32%) 0.079 10 (58.82%) 24 (54.55%) 1
Smoking, n (%) 1 (10%) 16 (34.04%) 0.153 1 (5.88%) 4 (9.09%) 0.06
BMI, mean (±SD) 26.39 (±3.34) 25.23 (±4.07) 0.309 29.95 (±3.73) 25.9 (±5.2) 0.58
Alcohol, n (%) (daily intake) 0 0 0.955 0 0 0.87
Diabetes mellitus, n (%) 0 3 (6.38%) 1 2 (11.76%) 3 (6.82%) 0.61
Hypertension, n (%) 2 (20%) 9 (19.15%) 1 4 (23.53%) 15 (34.09%) 0.54
Metabolic syndrome, n (%) 0 4 (8.51%) 1 4 (23.53%) 7 (15.91%) 0.48
HAQ, mean (±SD) 0.35 (±0.94) 0.17 (±0.32) 0.684 0.34 (±0.3) 0.37 (±0.42) 0.87
VAS, mean (±SD) 2.56 (±2.52) 1.73 (±2.37) 0.254 4.35 (±2.17) 3.56 (±2.4) 0.18
PASI, mean (±SD) 4.52 (±2.58) 3.65 (±3.41) 0.153 3.86 (±2.69) 4.53 (±6.46) 0.59
NAPSI, mean (±SD) 8 (±7.05) 9.31 (±8.86) 0.903 13.44 (±8.43) 5.29 (±5.94) 0.03
BMI, body mass index; HAQ, Health Assessment Questionnaire; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity 
Index; PsO, psoriasis alone; PsOAr, psoriatic patients with arthralgia; VAS, Visual Analogue Scale.
All underwent full clinical and US examinations: a total 
number of 7350 joints and 2100 entheses were scanned.
Patient characteristics
The mean (±SD) age in years was 50.49 (±12.27) in PsOAr, 
50.65 (±16.62) in PsO and 47.91 (±13.03) in HCs, without 
significant differences between groups (table 2). PsO 
group comprised a lower percentage of female (49.1%) 
compared with HCs (69.6%) (p=0.03), and with PsOAr 
(55.7%) (p=0.58). As expected, the body mass index 
(BMI) was significantly higher in PsOAr (26±4.8) and 
PsO (25±3.95), while in HCs was 23±3.67 (p=0.001 and 
0.002, respectively). Depression and hypertension were 
more frequent in PsOAr cohort than in HCs, but without 
differences between psoriasis cohorts. Considering the 
musculoskeletal complaint, PsOAr, compared with PsO, 
had a higher VAS pain (4±2.35 vs 2±2.39, p<0.001), 
tender joints count (2.98±4.7 vs 0.49±0.98, p<0.001) and 
tender enthesis count (0.64±1.14 vs 0.09±0.34, p<0.001) 
(table 2). All these variables were also significantly 
higher in PsOAr compared with HCs. No significant 
differences emerged between PsO and HCs for VAS pain 
(2±2.39 vs 2±2, p=0.97), tender joints count (0.49±0.98 vs 
0.37±1.1, p=0.13) and tender enthesis count (0.09±0.34 vs 
0.02±0.13, p=0.17) (table 2). PASI and NAPSI scores were 
similar between PsOAr and PsO.
Ultrasonographic inflammatory features
In the PsOAr cohort, 18 out of the 61 (29.5%) patients 
showed tenosynovitis in at least one region as evaluated 
by GS (grade 1 in 17/18 patients and grade 2 in 1/18), 
compared with 3 out of the 57 PsO patients (5.3%) 
(p<0.001) and 2/57 (3.5%) in HCs, all grade 1 for PsO 
and HCs (figure 1). Conversely, no significant differ-
ence was found between cohorts when tenosynovitis 
was analysed for PD. The presence of at least one active 
region of synovitis and active enthesitis, although more 
frequent in PsOAr compared with PsO (34.4% vs 26.3% 
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Table 4 Comparison of the baseline clinical and US variables between patients (with a follow-up of at least 3 months) 
without development of PsA and those developed PsA
PsO+PsOAr without PsA 
development (n=96)
PsO+PsOAr with PsA 
development (n=6) P value
Age, mean (±SD) 50.23 (±15.25) 59.17 (±8.75) 0.15
Female, n (%) 54 (56.25 %) 3 (50 %) 1
Smoking, n (%) 18 (18.75 %) 0 (0 %) 0.62
BMI, mean (±SD) 25 (±4.29) 28 (±3.16) 0.08
Family history of PsA, n (%) 14 (14.74 %) 1 (16.67 %) 1
VAS pain (0–10), mean (±SD) 2.63 (±2.35) 5.92 (±2.01) <0.01
HAQ, mean (±SD) 0.26 (±0.38) 0.44 (±0.22) 0.03
Tender joints count, mean (±SD) 1.74 (±3.16) 6.8 (±10.87) 0.03
Tender enthesis count, mean (±SD) 0.29 (±0.60) 1 (±2.45) 0.96
Active synovitis, n* (%) 20 (20.83 %) 2 (33.33 %) 0.61
Active synovitis, mean joint number (±SD) 0.3 (±0.68) 1 (±1.67) 0.31
Active enthesitis, n† (%) 21 (21.88 %) 4 (66.67 %) 0.03
Active enthesitis, mean entheseal number (±SD) 0.27 (±0.55) 0.67 (±0.52) 0.03
GS tenosynovitis, n‡ (%) 19 (19.8%) 1 (16.7%) 1
GS tenosynovitis, mean (±SD) 0.41 (1.07) 0.25 (1.22) 0.97
Values in bld signifies p value ≤0.05.
*Number of patients with at least one active synovitis.
†Active enthesitis.
‡Tenosynovitis in GS.
BMI, body mass index; GS, grey scale; HAQ, Health Assessment Questionnaire; HC, healthy control; PsA, psoriatic arthritis; PsO, psoriasis 
alone; PsOAr, psoriasis patients with arthralgia; US, ultrasonography; VAS, Visual Analogue Scale.
and 27.9% vs 17.5%, respectively) did not significantly 
differ (p=0.42 and 0.2, respectively). In addition, no other 
significant differences between PsOAr and PsO were 
found as regard bursitis or peritendinitis. Active synovitis 
and active enthesitis significantly differed between both 
PsOAr versus HCs and PsO versus HCs (figure 1).
Ultrasonographic structural/damage features
In PsOAr, 9 out of the 61 patients (14.7%) showed at least 
one entheseal erosion compared with 3 out of the 57 PsO 
patients (5.3%) (p=0.13) and none of the HCs (p=0.003) 
(figure 1).
The mean number of enthesophyte per patient 
was significantly different comparing cases with HCs 
(4.33±2.84 in PsOAr and 3.45±2.7 in PsO vs 2.11±2.17 in 
HCs, p<0.01), but was not substantially different between 
PsOAr and PsO (figure 1). No significant differences 
between the three cohorts were found for articular 
erosions and osteoproliferation (figure 1).
correlation between the sonographically detected inflammation 
and the baseline clinical variables
In the PsOAr cohort, both patients with US determined 
active synovitis and active enthesitis had higher NAPSI 
value (13.7±7.74 vs 5.07±6.18, p=0.01 and 13.4±8.4 vs 
5.3±5.9, p=0.03, respectively) (table 3). This was not 
observed in the PsO cohort, where only the age (ie, 
older) was associated with active synovitis (58.9 years±11.4 
vs 47.7 years±17.3, p=0.02) (table 3) and entheseal 
hypoechogencity and/or thickening (55.8 years±17.9 
vs 48.4 years±15.8, p=0.04). Evaluating together PsOAr 
and PsO (n=118), US determined active enthesitis was 
found more frequently in non-smoker patients (21.9% vs 
7.4%, p=0.009) but also in enthesopathy (ie, entheseal 
hypoechogencity and/or thickening) regardless enthe-
seal PD signal (25.9% vs 4.8%, p=0.002). A similar result 
was close to statistical significance also for active syno-
vitis (p=0.07); furthermore, the presence of US active 
enthesitis was associated with higher VAS pain (3.7±2.4 
vs 2.6±2.5, p=0.03).
longitudinal study
One hundred and two patients (54 in PsOAr and 48 in 
PsO cohort), with full clinical data and with a follow-up 
of at least 3 months, were included. The mean time 
of follow-up was 309.6±113.6 days (median 312, IQR 
233–354 days) in PsOAr and 566.2±187.6 days (median 
617.5, IQR 601–674 days) in PsO. Five patients in PsOAr 
cohort and one patient in PsO developed PsA, with an 
incidence rate of 109.2/1000 person-years in PsOAr and 
13.4/1000 person-years in PsO (p=0.03). Patients which 
developed PsA had significantly higher VAS pain at base-
line (5.92±2.01 vs 2.63±2.35, p=0.004), HAQ (0.44±0.22 
vs 0.26±0.38, p=0.03), joints tenderness (6.8±10.87 vs 
1.74±3.16, p=0.03). Sonographically determined active 
enthesitis (0.67±0.52 vs 0.27±0.55, p=0.03) was also 
associated with disease evolution (table 4). However, 
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tenosynovitis which was most strongly linked to non-spe-
cific symptoms at baseline was not linked to PsA develop-
ment in these cohorts (table 4).
dIsCussIOn
This is the first study to perform a combined clinical and 
US analysis on the transition phase of PsA, here defined 
as PsOAr. Through the prospective assessment, the PsOAr 
cohort showed a significantly higher incidence rate of PsA 
compared with PsO, consistent with the previous clinical 
observations that non-specific musculoskeletal symptoms 
were a risk factor for PsA development.7 18 We found that 
sonographically determined synovitis, enthesitis and teno-
synovitis were numerically more frequent in the PsOAr 
group compared with PsO. However, only tenosynovitis, 
evaluated in GS, showed a strong significant association 
with baseline PsOAr. This evidence suggests that tenosyn-
ovitis could be an important contributor to non-specific 
musculoskeletal symptoms in patients with psoriasis, while 
synovitis and enthesitis may also occur without symptoms. 
Although the numbers were small, our study suggests that 
sonographically determined enthesitis was linked to the 
future evolution of PsA, while tenosynovitis was not. This 
detection supports the cardinal role of enthesitis observed 
in experimental models of PsA and in also some imaging 
studies.13 19 Moreover, previous observations showed that 
accessory pulley as mini-entheses may provide a mecha-
nistic link between enthesitis and tenosynovitis but further 
work is needed.20 21 In this study, it is interesting to note 
that psoriatic nail involvement correlated with subclinical 
inflammation, but only in the arthralgia cohort. Higher 
NAPSI values were indeed found in PsOAr patients with 
sonographically determined active synovitis and active 
enthesitis, confirming the nail involvement as a marker of 
musculoskeletal inflammation in patients with psoriasis.22 23 
In this PsO cohort, as already described in patients with 
psoriasis without musculoskeletal complaints, age was asso-
ciated with active synovitis.9 24
Furthermore, the positive correlation found between 
US enthesitis and non-smoking status seems to suggest 
a relationship between smoking status and the develop-
ment of sonographically detected entheseal inflammation. 
This observation supports the apparent paradox in which 
smoking could favour psoriasis but could be inversely asso-
ciated with PsA among patients with psoriasis.13 25
The limitations of this study included the small 
numbers and relative short follow-up, but the findings 
are in agreement with previous literature.7 18 Moreover, 
the evaluation of arthralgia as present versus absent 
without reporting the anatomical sites of arthralgia will 
need to be addressed in future studies. These findings 
need replication in bigger cohorts, also with the aim of 
constructing a predictive model for development of PsA, 
which was not feasible due to the low number of events 
(ie, PsA development) and the wide range of possible 
clinical and US predictors. In conclusion, these prelim-
inary results identified and stratified, using both clinical 
and ultrasound, a subgroup of patients with psoriasis 
more prone to develop PsA, that is, PsOAr, in which a 
strict rheumatological monitoring or disease intercep-
tion with psoriasis directed therapy could be envisaged.
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